Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Pimivalimab |
Synonyms | |
Therapy Description |
Pimivalimab (JTX-4014) is a monoclonal antibody that targets PD-1 (PDCD1), potentially resulting in restoration of anti-tumor immune response (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Pimivalimab | JTX4014|JTX 4014|JTX-4014 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 122 | Pimivalimab (JTX-4014) is a monoclonal antibody that targets PD-1 (PDCD1), potentially resulting in restoration of anti-tumor immune response (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 over exp | pleomorphic adenoma carcinoma | predicted - sensitive | Pimivalimab | Case Reports/Case Series | Actionable | In a Phase I trial, Pimivalimab (JTX-4014) treatment led to a partial response that was ongoing for at least 386 days in a patient with CD274 (PD-L1)-positive (100% staining) carcinoma ex-pleomorphic adenoma (PMID: 32989552; NCT03790488). | 32989552 |
CD274 positive | ovarian cancer | predicted - sensitive | Pimivalimab | Case Reports/Case Series | Actionable | In a Phase I trial, Pimivalimab (JTX-4014) treatment led to a partial response lasting 232 days in a patient with CD274 (PD-L1)-positive (5% staining) ovarian cancer (PMID: 32989552; NCT03790488). | 32989552 |
CD274 positive | mucoepidermoid carcinoma | predicted - sensitive | Pimivalimab | Case Reports/Case Series | Actionable | In a Phase I trial, Pimivalimab (JTX-4014) treatment led to a complete response that was ongoing for at least 338 days in a patient with CD274 (PD-L1)-positive (60% staining) mucoepidermoid carcinoma of the parotid (PMID: 32989552; NCT03790488). | 32989552 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03790488 | Phase I | Pimivalimab | Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies | Completed | USA | 0 |